145 related articles for article (PubMed ID: 19761819)
21. Phase I randomized clinical trial of N-acetylcysteine in combination with an adjuvant probenecid for treatment of severe traumatic brain injury in children.
Clark RSB; Empey PE; Bayır H; Rosario BL; Poloyac SM; Kochanek PM; Nolin TD; Au AK; Horvat CM; Wisniewski SR; Bell MJ
PLoS One; 2017; 12(7):e0180280. PubMed ID: 28686657
[TBL] [Abstract][Full Text] [Related]
22. Morphine blood-brain barrier transport is influenced by probenecid co-administration.
Tunblad K; Jonsson EN; Hammarlund-Udenaes M
Pharm Res; 2003 Apr; 20(4):618-23. PubMed ID: 12739770
[TBL] [Abstract][Full Text] [Related]
23. Effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in rats and rabbits.
Kim SH; Kim WB; Lee MG
Antimicrob Agents Chemother; 1999 Jan; 43(1):96-9. PubMed ID: 9869572
[TBL] [Abstract][Full Text] [Related]
24. Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.
Landersdorfer CB; Kirkpatrick CM; Kinzig M; Bulitta JB; Holzgrabe U; Drusano GL; Sörgel F
Antimicrob Agents Chemother; 2009 Sep; 53(9):3902-7. PubMed ID: 19564368
[TBL] [Abstract][Full Text] [Related]
25. Low-dose probenecid selectively inhibits urinary excretion of phenolsulfonphthalein in rats without affecting biliary excretion.
Shin YJ; Lee JH; Oh JH; Lee YJ
J Appl Toxicol; 2013 Jun; 33(6):511-5. PubMed ID: 22161506
[TBL] [Abstract][Full Text] [Related]
26. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes.
Acheampong AA; Shackleton M; John B; Burke J; Wheeler L; Tang-Liu D
Drug Metab Dispos; 2002 Apr; 30(4):421-9. PubMed ID: 11901096
[TBL] [Abstract][Full Text] [Related]
27. Probenecid is a chemosensitizer in cancer cell lines.
Campos-Arroyo D; Martínez-Lazcano JC; Melendez-Zajgla J
Cancer Chemother Pharmacol; 2012 Feb; 69(2):495-504. PubMed ID: 21861129
[TBL] [Abstract][Full Text] [Related]
28. Efflux of a suppressive neurotransmitter, GABA, across the blood-brain barrier.
Kakee A; Takanaga H; Terasaki T; Naito M; Tsuruo T; Sugiyama Y
J Neurochem; 2001 Oct; 79(1):110-8. PubMed ID: 11595763
[TBL] [Abstract][Full Text] [Related]
29. Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study.
Scism JL; Powers KM; Artru AA; Lewis L; Shen DD
Brain Res; 2000 Nov; 884(1--2):77-86. PubMed ID: 11082489
[TBL] [Abstract][Full Text] [Related]
30. Effect of Efflux Transporter Inhibition on the Distribution of Fluconazole in the Rat Brain.
Wang W; Zheng N; Zhang J; Huang X; Yu S
Neurochem Res; 2017 Aug; 42(8):2274-2281. PubMed ID: 28337665
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.
Ko H; Cathcart KS; Griffith DL; Peters GR; Adams WJ
Antimicrob Agents Chemother; 1989 Mar; 33(3):356-61. PubMed ID: 2729930
[TBL] [Abstract][Full Text] [Related]
32. Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat.
Wang C; Wang C; Liu Q; Meng Q; Cang J; Sun H; Peng J; Ma X; Huo X; Liu K
Drug Metab Dispos; 2014 Jun; 42(6):996-1007. PubMed ID: 24692216
[TBL] [Abstract][Full Text] [Related]
33. Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.
Klecker RW; Jamis-Dow CA; Egorin MJ; Erkmen K; Parker RJ; Stevens R; Collins JM
Drug Metab Dispos; 1994; 22(2):254-8. PubMed ID: 7912177
[TBL] [Abstract][Full Text] [Related]
34. Comparative renal excretion of VX-702, a novel p38 MAPK inhibitor, and methotrexate in the perfused rat kidney model.
Tamhane M; Chakilam AR; Jayaraj A; Thakkar V; Taft DR
Drug Dev Ind Pharm; 2010 Mar; 36(3):315-22. PubMed ID: 20170280
[TBL] [Abstract][Full Text] [Related]
35. Ocular pharmacokinetics profile of different indomethacin topical formulations.
Bucolo C; Melilli B; Piazza C; Zurria M; Drago F
J Ocul Pharmacol Ther; 2011 Dec; 27(6):571-6. PubMed ID: 22059858
[TBL] [Abstract][Full Text] [Related]
36. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
Yasui-Furukori N; Uno T; Sugawara K; Tateishi T
Clin Pharmacol Ther; 2005 Jan; 77(1):17-23. PubMed ID: 15637527
[TBL] [Abstract][Full Text] [Related]
37. Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%.
Glogowski S; Lowe E; Siou-Mermet R; Ong T; Richardson M
J Ocul Pharmacol Ther; 2014 Feb; 30(1):66-73. PubMed ID: 24325539
[TBL] [Abstract][Full Text] [Related]
38. Effect of the organic acid transport inhibitor probenecid on renal cortical uptake and proximal tubular toxicity of hexachloro-1,3-butadiene and its conjugates.
Lock EA; Ishmael J
Toxicol Appl Pharmacol; 1985 Oct; 81(1):32-42. PubMed ID: 4049419
[TBL] [Abstract][Full Text] [Related]
39. Effect of probenecid on depolarizations evoked by N-methyl-D-aspartate (NMDA) in the rat striatum.
Urenjak J; Obrenovitch TP; Zilkha E
Naunyn Schmiedebergs Arch Pharmacol; 1997 Jan; 355(1):36-42. PubMed ID: 9007840
[TBL] [Abstract][Full Text] [Related]
40. Effect of capillary efflux transport inhibition on the determination of probe recovery during in vivo microdialysis in the brain.
Sun H; Bungay PM; Elmquist WF
J Pharmacol Exp Ther; 2001 Jun; 297(3):991-1000. PubMed ID: 11356921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
